Learn More about Next Investors - Experts in Biotech Stocks
What’s Happening to the CPH Share Price?
Next Investors Dec 02, 2020
Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.
Short Term Trade Update: What’s Happening to the CPH Share Price?
Next Investors Dec 02, 2020
We put out a short note on Creso Pharma (ASX: CPH) to some of you that might have previously invested in the stock and not had a positive experience. After a couple of false starts, our plan is to ride this momentum over the coming weeks and hopefully recoup some of our previous losses.
Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH
Next Investors Archived Oct 13, 2020
While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.
We are Rolling the Dice on this One…
Next Investors Oct 13, 2020
Long term Creso Pharma (ASX: CPH) shareholders have had a rough ride in the last 12 months. Last week the $20M capped CPH raised circa A$9M at $0.0291 per share, finally extinguishing the company’s debt and ridding the company of major con note holders that were hampering any share price appreciation.
$2.6M Capped eSense-Lab Signs US$600k Revenue Deal
Next Investors Archived Jun 19, 2020
Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.
CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough
Next Investors Archived Feb 06, 2020
Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,
CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone
Next Investors Archived Jan 28, 2020
Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.
CPH Kick Start African Launch - $300k Order Values Confirmed
Next Investors Archived Dec 09, 2019
Creso Pharma (ASX:CPH | FRA:1X8) has announced that through Pharma Dynamics, Creso’s partner in the African region, initial orders worth approximately A$300,000 for the cannaQIX® product range have been made.